Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label pazopanib study in unresectable or locally advanced dermatofibrosarcoma protuberans
2009-014096-46Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in dermatofibrosarcoma protuberans (DFSP), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical response rate at 6 months. Started Aug 2009; status: active.
02
Drugs
pazopanib
03
Conditions
dermatofibrosarcoma protuberans (DFSP)
Beyond the preview
Go deeper on 2009-014096-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014096-46.